One-Page Company Memo
Generate an institutional one-pager for any company in the universe — business, drivers, risks, valuation, bull/bear/base case and what to track. Auto-synthesized from the data layer.
Generates a clean, one-page institutional research memo for any company — the kind of summary an analyst would put in front of an investment committee.
Click a company name to switch. The memo reads top-to-bottom: business, drivers, risks, then bull / bear / base cases and what to monitor. The sidebar has the key numbers and scores. Print to PDF with Ctrl/Cmd+P.
- Bull / bear / base
- — The optimistic, pessimistic and most-likely scenarios for the company.
- What to track
- — The handful of signals that would confirm or break the thesis.
Rubicon Research
Rubicon Research (founded 1999, promoted by General Atlantic) is among the few Indian pharma companies with a near-complete focus on the US / regulated markets. It develops complex/differentiated generics, specialty products and drug-device combinations using proprietary novel-drug-delivery platforms. It IPO'd on the NSE & BSE on 16-Oct-2025 (issue ₹485) and trades around ₹1,257 (Jun-2026), ~2.6× the issue price. FY25 revenue ₹1,284 Cr (3-yr revenue CAGR >80%), with 72 active ANDAs and 9 NDAs approved.
Domestic 2% · US Generics 72% · CDMO 8% · RoW 8% · Specialty 10%
Complex/specialty US launches, drug-device & 505(b)(2) pipeline, Pithampur capacity
Product/facility concentration & USFDA dependence; rich valuation (~104× P/E)
Differentiated Formulations / Specialty (US-focused)
Rubicon Research screens as a high-quality complex generics franchise. With revenue of ₹1.3K Cr growing ~81% and 20.7% EBITDA margins, the base case is steady compounding driven by complex/specialty us launches, drug-device & 505(b)(2) pipeline, pithampur capacity, while watching product/facility concentration & usfda dependence; rich valuation (~104× p/e).
Trades at 104x P/E, 55.0x EV/EBITDA and 12.0x P/B. A premium to the sector — justified only if growth and returns hold.
- • Complex/specialty US launches, drug-device & 505(b)(2) pipeline, Pithampur capacity underpins a 81% 5Y revenue CAGR.
- • Operating leverage as scale builds toward higher margins (currently 20.7% EBITDA).
- • Capacity already in place to support the next growth phase.
- • Product/facility concentration & USFDA dependence; rich valuation (~104× P/E).
- • ~72% US exposure leaves earnings sensitive to price erosion and FDA action.
- • Valuation at 104x P/E prices in continued execution — little margin for error.
- 1USFDA facility status & ANDA approval cadence
- 2Gross-margin trajectory & new-launch contribution
- 3R&D productivity (filings/approvals per ₹ of R&D)
- 4Capital allocation — capex payback & M&A discipline
Listed on NSE/BSE 16-Oct-2025 at ₹485; trading ~₹1,257 (11-Jun-2026, mcap ₹21,088 Cr, ~104× trailing P/E) — ~2.6× the issue price, so trailing 1Y/3Y/5Y CAGRs are not yet meaningful. FY25 financials from the DRHP/post-IPO disclosures. Revenue-mix, EV/EBITDA & P/B are modeled (reported book value is thin post-OFS).